Immunology of atherosclerosis

References
1 Virchow R. Cellular pathology as based upon physiological and pathological history. Classics of Medicine library, Birmingham, Alabama. 1958
2 Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell.. Science 1973; 180: 1332-1339.
3 Ross R.. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340: 115-126.
4 Yan ZQ, Hansson GL. innate immunity, macrophage activation and atherosclerosis. Immunol Rev 2007; 219: 187-203.
5 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354: 610-621.
6 Hansson GK, Libby P. The immune response in atherosclerosis: a double edged sword. Nat Rev Immunol 2006; 6: 508-519.
7 Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets in atherosclerosis. Nat Rev Immunol 2008; 8: 802-815.
8 Galkina E, Ley K. Immune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2009; 27: 165-197.
9 Lutgens E, Lievens D, Beckers L. et al Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med 2010; 207: 391-404.
10 Ait-Oufella H, Herbin O, Bouaziz JD. et al B cell depletion reduces the development of atherosclerosis in mice. J Exp Med 2010; 207: 1579-1587.
11 Kyaw T, Tay C, Krishnamurthi S. et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res 2011; 109: 830-840.
12 Chou MY, Fogelstrand L, Hartvigsen K. et al. Oxidation specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest 2009; 119: 1335-1349.
13 Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
14 Wolfs I, Donners M, de Winther M. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarization. Thromb Haemost 2011; 106: 763-771.
15 Manthey H, Zernecke A. Dendritic cells in the pathogenesis of atherosclerosis: immune regulation and beyond. Thromb Haemost 2011; 106: 772-778.
16 Ketelhuth D, Hansson G. Cellular immunity, LDL and atherosclerosis: break of tolerance in the arthery wall. Thromb Haemost 2011; 106: 779-786.
17 Butcher M, Galkina E. Current view on the role of IL-17-producing cells in atherosclerosis. Thromb Haemost 2011; 106: 787-795.
18 de Jager SCA, Kuiper J. Vaccination strategies in atherosclerosis. Thromb Haemost 2011; 106: 796-803.
19 Gerdes N, Zirlik A. Costimulation - the Yin and Yang in atherosclerosis?. Thromb Haemost 2011; 106: 804-813.
20 Getz G, Van der Laan P, Reardon C. Natural killer T cells in lipoprotein metabolism and atherosclerosis. Thromb Haemost 2011; 106: 814-819.
21 Bot I, Biessen E. Mast cells in atherosclerosis. Thromb Haemost 2011; 106: 820-826.
22 Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011; 106: 827-838.
23 Drechsler M, Döring Y, Megens RTA. et al. Neutrophilic granulocytes - promiscuous accelerators of atherosclerosis. Thromb Haemost 2011; 106: 839-848.
24 Wade NS, Major A. The problem of accelerated atherosclerosis in systemic lupus erythematosus: Insights into a complex co-morbidity. Thromb Haemost 2011; 106: 849-857.
25 Rosenfeld M, Campbell LA. Pathogens and Atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Thromb Haemost 2011; 106: 858-867.